Correction: Disease course and treatment responses in children with relapsing myelin oligodendrocyte glyco-protein antibody–associated disease (JAMA Neurology (2018) DOI: 10.1001/jamaneurol.2017.4601);Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody–Associated disease

JAMA Neurology

Volumn 75, Issue 4, 2018, Pages 478-487

  Hacohen, Yael ^a,b   Wong, Yu Yi ^c   Lechner, Christian ^d   Jurynczyk, Maciej ^e   Wright, Sukhvir ^f   Konuskan, Bahadir ^g   Kalser, Judith ^h   Poulat, Anne Lise ⁱ   Maurey, Helene ^j,k   Ganelin Cohen, Esther ^l,m   Wassmer, Evangeline ^f   Hemingway, Chery ^b   Forsyth, Rob ⁿ   Hennes, Eva Maria ^o   Isabel Leite, M ^e   Ciccarelli, Olga ^a   Anlar, Banu ^g   Hintzen, Rogier ^c   Marignier, Romain ^p,q   Palace, Jacqueline ^e   Baumann, Matthias ^d   Rostásy, Kevin ^r   Neuteboom, Rinze ^c   Deiva, Kumaran ^j   Lim, Ming ^s,t   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^f BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^g HACETTEPE UNIVERSITY   (Turkey)

^h LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

ⁱ HOSPICES CIVILS DE LYON   (France)

^j BICÊTRE HOSPITAL   (France)

^k UNIVERSITÉ PARIS SACLAY   (France)

^l SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^m TEL AVIV UNIVERSITY   (Israel)

ⁿ NEWCASTLE UNIVERSITY   (United Kingdom)

^o OLGAHOSPITAL   (Germany)

^p HÔPITAL NEUROLOGIQUE   (France)

^q UNIVERSITÉ LYON 1   (France)

^r UNIVERSITY OF WITTEN HERDECKE   (Germany)

^s IMPERIAL COLLEGE LONDON   (United Kingdom)

^t KING'S COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; GLATIRAMER; IMMUNOGLOBULIN; MYCOPHENOLATE MOFETIL; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; RITUXIMAB; AUTOANTIBODY; IMMUNOLOGIC FACTOR; MERCAPTOPURINE; MYCOPHENOLIC ACID;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; AGE; ARTICLE; CHILD; CHILD HEALTH; CLINICAL FEATURE; CLINICAL PROTOCOL; DEMOGRAPHY; DEMYELINATING DISEASE; DISEASE COURSE; ETHNICITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOOPTIC NEUROPATHY; OPTIC NEURITIS; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOGRAPHY; RELAPSE; RELAPSING MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY ASSOCIATED DISEASE; SEX RATIO; TREATMENT RESPONSE; BLOOD; COHORT ANALYSIS; DISABILITY; EUROPE; IMMUNOLOGY; INTERNATIONAL COOPERATION; RECURRENT DISEASE; TREATMENT OUTCOME;

AUTOANTIBODIES; COHORT STUDIES; DISABILITY EVALUATION; EUROPE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERNATIONAL COOPERATION; MALE; MERCAPTOPURINE; MYCOPHENOLIC ACID; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; NEUROMYELITIS OPTICA; RECURRENCE; RITUXIMAB; TREATMENT OUTCOME;

EID: 85045131343     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2018.0446     Document Type: Erratum

References (30)

1. Reindl M, Jarius S, Rostasy K, Berger T. Myelin oligodendrocyte glycoprotein antibodies: how clinically useful are they? Curr Opin Neurol. 2017;30 (3):295-301.
2. Tenembaum S, Chitnis T, Nakashima I, et al. Neuromyelitis optica spectrum disorders in children and adolescents. Neurology. 2016;87(9)(suppl 2): S59-S66.
3. Ketelslegers IA, Van Pelt DE, Bryde S, et al. Anti-MOG antibodies plead against MS diagnosis in an acquired demyelinating syndromes cohort. Mult Scler. 2015;21(12):1513-1520.
4. Hacohen Y, Absoud M, Deiva K, et al. Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurol Neuroimmunol Neuroinflamm. 2015;2(2):e81.
5. Hennes EM, Baumann M, Schanda K, et al; BIOMARKER Study Group. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology. 2017;89(9): 900-908.
6. Baumann M, Hennes EM, Schanda K, et al. Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): Extending the spectrum of MOG antibody positive diseases. Mult Scler. 2016;22(14):1821-1829.
7. Rostasy K, Mader S, Schanda K, et al. Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol. 2012;69(6):752-756.
8. Huppke P, Rostasy K, Karenfort M, et al. Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients. Mult Scler. 2013;19(7):941-946.
9. Lechner C, Baumann M, Hennes EM, et al. Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease. J Neurol Neurosurg Psychiatry. 2016;87(8): 897-905.
10. Sepúlveda M, Armangue T, Martinez-Hernandez E, et al. Clinical spectrum associated with MOG autoimmunity in adults. J Neurol. 2016;263(7):1349-1360.
11. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol. 2014;71(3):276-283.
12. Hacohen Y, Mankad K, Chong WK, et al. Diagnostic algorithm for relapsing acquired demyelinating syndromes in children. Neurology. 2017;89(3):269-278.
13. Kitley J, Palace J. Therapeutic options in neuromyelitis optica spectrum disorders. Expert Rev Neurother. 2016;16(3):319-329.
14. Zamvil SS, Slavin AJ. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm. 2015;2(1):e62.
15. Reindl M, Rostasy K. MOG antibody-associated diseases. Neurol Neuroimmunol Neuroinflamm. 2015;2(1):e60.
16. Sepúlveda M, Armangué T, Sola-Valls N, et al. Neuromyelitis optica spectrum disorders: comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm. 2016;3(3):e225.
17. Montcuquet A, Collongues N, Papeix C, et al. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler. 2016;23(10):1377-1384.
18. Krupp LB, Tardieu M, Amato MP, et al; International Pediatric Multiple Sclerosis Study Group. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler. 2013;19(10):1261-1267.
19. Wingerchuk DM, Banwell B, Bennett JL, et al; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189.
20. Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014;83(2): 142-150.
21. Waters P, Woodhall M, O’Connor KC, et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm. 2015;2(3):e89.
22. Nave KA. Myelination and support of axonal integrity by glia. Nature. 2010;468(7321):244-252.
23. Reindl M, Di Pauli F, Rostásy K, Berger T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol. 2013;9(8): 455-461.
24. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis. Lancet Neurol. 2013;12(2):157-165.
25. Deiva K, Absoud M, Hemingway C, et al; UK Childhood Inflammatory Demyelination (UK-CID) Study and French Kidbiosep Study. Acute idiopathic transverse myelitis in children. Neurology. 2015;84 (4):341-349.
26. Marignier R, Cobo Calvo A, Vukusic S. Neuromyelitis optica and neuromyelitis optica spectrum disorders. Curr Opin Neurol. 2017;30(3): 208-215.
27. Azzopardi L, Cox AL, McCarthy CL, Jones JL, Coles AJ. Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. J Neurol. 2016;263(1):25-29.
28. Wildemann B, Jarius S, Schwarz A, et al. Failure of alemtuzumab therapy to control MOG encephalomyelitis. Neurology. 2017;89(2):207-209.
29. Kile S, Au W, Parise C, et al. IVIG treatment of mild cognitive impairment due to Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2017;88(2): 106-112.
30. Winter M, Baksmeier C, Steckel J, et al. Dose-dependent inhibition of demyelination and microglia activation by IVIG. Ann Clin Transl Neurol. 2016;3(11):828-843.